Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Claire on +44 1494 818025 or claire@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Claire Roberts
Sales Director
claire@zenopa.com
+44 1494 818025

Testimonials
I just wanted to thank you and the rest of the team for all your help and support in enabling me to gain my new role.
Sally, 2011

Sanofi-aventis makes bid to acquire Genzyme

1 September 2010 00:00 in Pharmaceutical Company Restructures


Sanofi-aventis has made a bid to acquire fellow pharmaceutical company Genzyme as part of its future development plans.

The company has addressed a letter to Genzyme's chairman, president and chief executive officer Henri Termeer detailing a non-binding proposal to purchase the firm for $18.5 billion (12 billion pounds) in cash.

Sanofi-aventis believes that its offer would deliver significant value to Genzyme's shareholders, while simultaneously creating a new global leader in the pharmaceuticals market.

The deal would see Genzyme become Sanofi-aventis' global centre for excellence in rare diseases, allowing both firms to more easily develop new treatments and improve penetration in existing and expanding markets.

Christopher Viehbacher, chief executive officer of Sanofi-aventis, said: "A combination with Genzyme represents a compelling opportunity for both companies and our respective shareholders and is consistent with our sustainable growth strategy."

Last month, Sanofi-aventis published its financial results for the second quarter of the year, reporting a year-on-year earnings improvement of 4.5 per cent.ADNFCR-8000103-ID-800046974-ADNFCR

Other news stories from 01/09/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd